Copy to clipboard 
Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE’s double-digit growth drove the company’s performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor’s supply issues in the second quarter of last year. Bioventus expects growth to accelerate in the second half of 2025.
Bioventus announced it is expanding its pain treatment portfolio with the addition of platelet-rich plasma systems as the exclusive U.S. distributor of XCELL PRP systems from APEX Biologix. The revenue impact in 2025 is expected to be immaterial.
Likewise, massive comps from last year caused an expected slowdown in bone graft substitutes, but the category will accelerate in the second half on the strength of recently added distributors.
Exogen grew 4% and could sustain that level of growth through 2025.
Bioventus reiterated its 2025 guidance of total revenue organic growth between 6% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $89.0 | $85.2 | $3.8 | 4.5% |
| Other | $22.0 | $19.5 | $2.5 | 12.8% |
| Total | $111.0 | $104.7 | $6.3 | 6% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $99.0 | $93.0 | $6.0 | 6.4% |
| OUS | $12.0 | $11.6 | $0.3 | 2.9% |
| Total | $111.0 | $104.7 | $6.3 | 6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $123.9 | |
| Cost of Sales | $40.8 | 33% |
| Selling and Admin | $73.5 | 59.3% |
| R&D | $3.0 | 2.4% |
| R&D | $3.0 | 2.4% |
| Other | $9.2 | 7.4% |
Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE's double-digit growth drove the company's performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor's supply issues in the second quarter of...
Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE’s double-digit growth drove the company’s performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor’s supply issues in the second quarter of last year. Bioventus expects growth to accelerate in the second half of 2025.
Bioventus announced it is expanding its pain treatment portfolio with the addition of platelet-rich plasma systems as the exclusive U.S. distributor of XCELL PRP systems from APEX Biologix. The revenue impact in 2025 is expected to be immaterial.
Likewise, massive comps from last year caused an expected slowdown in bone graft substitutes, but the category will accelerate in the second half on the strength of recently added distributors.
Exogen grew 4% and could sustain that level of growth through 2025.
Bioventus reiterated its 2025 guidance of total revenue organic growth between 6% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $89.0 | $85.2 | $3.8 | 4.5% |
| Other | $22.0 | $19.5 | $2.5 | 12.8% |
| Total | $111.0 | $104.7 | $6.3 | 6% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $99.0 | $93.0 | $6.0 | 6.4% |
| OUS | $12.0 | $11.6 | $0.3 | 2.9% |
| Total | $111.0 | $104.7 | $6.3 | 6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $123.9 | |
| Cost of Sales | $40.8 | 33% |
| Selling and Admin | $73.5 | 59.3% |
| R&D | $3.0 | 2.4% |
| R&D | $3.0 | 2.4% |
| Other | $9.2 | 7.4% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
